Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM.CD40L Vaccine + IL-2 in Mantle Cell Lymphoma
NCT00101101Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jul 2004
- Primary completion
- Oct 2012
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GM.CD40L in mantle cell lymphoma (MCL), sponsored by Moffitt Cancer Center. Started Jul 2004; status: completed.
02
Drugs
GM.CD40L
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00101101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00101101.